Landmark UK-US pharmaceuticals deal to safeguard medicines access and drive vital investment for UK patients and businesses

Milestone deal secures UK’s medicines access for patients, with a wide range of groundbreaking new treatments to reach NHS front-line quicker.

Tens of thousands of NHS patients will benefit from a landmark trade deal between the UK and the US, which will secure and expand access to vital drugs, safeguard our medicines supply chain, and drive crucial investment while supporting UK patients and industries. 

The deal – part of the UK-US Economic Prosperity Deal – sees the UK become the only country in the world to secure a zero percent tariff on pharmaceuticals to the US - protecting UK-based manufacturing and cementing our place as a world leader for life sciences investment. The deal will also secure preferential terms for the UK’s med tech exports meaning no additional new tariffs on medtech to unlock further investments in UK and a further boost to growth.

The move has secured the confidence of the pharmaceutical industry that the UK is a top destination for investment and growth, with major firms like Moderna, Bristol Myers Squibb,  and BioNTech investing billions here, driving renewed confidence in the UK and supporting the government’s ambition for the UK to become Europe’s leading life sciences economy by 2030.